Gilead wins a key battle with the CDC over Truvada patents; the latest C-suite moves made in biopharma

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: Gilead wins a key battle with the CDC over patents for its Truvada HIV pill By Ed Silverman Yichuan Cao/Sipa USA via AP Images The decision comes amid a broader fight between Gilead and the CDC over research and resulting patent rights to the medication. Read More STAT+: An Anavex study spin job sullies an otherwise spectacular Alzheimer's conference By Adam Feuerstein Molly Ferguson/STAT The company’s presentation was a textbook demonstration of the deep bag of tricks that can be deployed to spin results. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Sponsored Insight by Genentech How physicians and biotech are partnering to expand biomarker testing Personalized cancer care hinges on testing for the unique drivers of each person's cancer, but practical challenges keep many people from getting the tests they need. Learn how oncology care providers and biotech are working together to overcome biomarker testing barriers and expand access for patients everywhere. STAT+: Inside one startup's quest to build proteins from scratch using artificial intelligence By Ryan Cross — The Boston Globe Generate Bio A Somerville startup and an academic lab in Seattle say they have developed a way to use artificial intelligence to design proteins that don’t exist in nature. Proteins help people move, digest food, and fight infections — to name a few of their numerous functions. They’re also the basis of a nearly $300 billion drug industry for treating cancer, immune diseases, and other conditions. Most of these therapies are only slightly altered versions of natural proteins. And for some scientists, nature is too limiting. Read More Friday, December 2, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser